AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.

Authors

Lingying Wu

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Lingying Wu , Peng-Hui Wang , Sheng-Yen Hsiao , Chih-Long Chang , Hee Seung Kim , JUNG-YUN LEE , Sang-Young Ryu , Yunxia Zuo , Xiyan Mu , Yujuan Gao , Silu Yang , Jae-Kwan Lee

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Gastrointestinal Cancers Symposium

bookmark_border

AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).

First Author: Rui-hua Xu

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).

First Author: Rui-hua Xu

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.

First Author: Jianqing Zhu

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax‑TF‑ADC) in previously treated, recurrent or metastatic cervical cancer.

First Author: Robert L. Coleman